ClinicalTrials.gg
RecruitingNCT04014803ATTEMPTUpdated Feb 9, 2026

Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion

A Phase 4 interventional study of Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,500
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
Largest of 21
3,500 · median 520
Started
2020
the only one that year
Phase 4
5 of 31
1 open now
Primary completion
2027-06
later than 6 of 13 live
Registered
15th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one has the largest planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 4, reaches primary completion later than 6 of the 13 other live ones, and was the 15th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

This study is a prospective, open label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective percutaneous coronary intervention with drug eluting stents for complex coronary lesions.

Read the detailed description

Over the past several decades, dual antiplatelet therapy (DAPT) with the combination of aspirin and a P2Y12 inhibitor has become an essential treatment in patients undergoing percutaneous coronary intervention (PCI) to reduce ischemic events. Although the optimal duration of DAPT still remains controversial in patients with coronary artery disease, the recommended duration of maintenance of DAPT for patients undergoing PCI with drug-eluting stent is ≥12 months for those with acute coronary syndrome (ACS), and ≥6 months for those with stable coronary artery disease according to the current guidelines. However, individualized approach based on ischemic versus bleeding risks assessment is needed to determine the optimal duration of DAPT in various population.

Several studies reported that patients undergoing PCI for complex lesions had significantly higher rates of ischemic events than those with non-complex lesions. Moreover, prolonged DAPT of aspirin and clopidogrel more than 1 year significantly reduced the risk of cardiac ischemic events up to 44% in patients undergoing PCI for complex coronary lesions, and the current guideline recommends prolonged DAPT duration may be considered in patients undergoing complex PCI. Apart from prolonged use of DAPT, use of more potent P2Y12 inhibitor than clopidogrel may be another strategy to reduce ischemic events in patients undergoing PCI for complex coronary lesions. Prasugrel, a new thienopyridine, inhibits platelet aggregation more rapidly and potently than clopidogrel. In the TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel) study, prasugrel reduced ischemic events compared with clopidogrel in patients with acute coronary syndrome. Moreover, low dose prasugrel also reduced ischemic events without an excessive bleeding risk in Japanese population. Therefore, DAPT of aspirin and prasugrel would reduce recurrent ischemic events than DAPT of aspirin and clopidogrel in patients undergoing PCI for complex lesions, a high risk group of ischemic events, even when they do not present with myocardial infarction. So far, there have been no data on this issue.

The aim of the SMART-ATTEMPT (Aspirin and a PoTent P2Y12 inhibitor versus aspirin and clopidogrel Therapy in patients undergoing Elective percutaneous coronary intervention for coMPlex lesion Treatment) trial is to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective PCI for complex lesions.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Percutaneous Coronary Intervention
  • Dual Antiplatelet Therapy
  • Complex Coronary Lesion
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ① Subject must be at least 19 years of age
  • ② Subject who can verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written prior to any study related procedure
  • ③ Patients undergoing elective PCI as follows:

    1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5 mm size
    2. Chronic total occlusion (≥3 months) as target lesion
    3. PCI for unprotected left main disease (left main ostium, body, or distal bifurcation including non-true bifurcation lesions)
    4. Long coronary lesions (expected stent length ≥38 mm)
    5. Multi-vessel PCI (≥2 vessels treated at one PCI session)
    6. Multiple stent needed (≥3 stents per patient)
    7. In-stent restenosis lesion as target lesion
    8. Severely calcified lesion (encircling calcium in angiography)
    9. Ostial lesions of left anterior descending artery, left circumflex artery, or right coronary artery

Exclusion criteria

Exclusion Criteria:

  • ① Hemodynamic instability or cardiogenic shock
  • ② Subjects with serious bleeding (Intracerebral hemorrhage, gastrointestinal bleeding, hematuria, hemoptysis, and etc.)
  • ③ Previous history of intracerebral hemorrhage, , or stroke
  • ④ Known or to study medications (aspirin, clopidogrel, and prasugrel)
  • ⑤ Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
  • ⑥ Non-cardiac co-morbid conditions are present with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • ⑦ Patients presenting with biomarker positive acute coronary syndrome
  • ⑧ Patients chronically taking prasugrel or ticagrelor (≥1 week)
  • ⑨ Subjects ≥75 years of age or \<60 kg of body weight
  • ⑩ Patients taking warfarin or novel oral anticoagulants (dabigatran, rivaroxaban, edoxaban, or apixaban)

    • Eligible patients will be randomly assigned to treatment arms, stratified by participating centers, presence of diabetes mellitus, and stent types.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,500 participants (estimated)

Study arms

  • Active comparator
    Prasugrel plus Aspirin arm

    Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily\* will be given for one year. \* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement.

    Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin

  • Active comparator
    Clopidogrel plus Aspirin arm

    Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.

    Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin

Interventions

  • DrugDual antiplatelet therapy with a P2Y12 inhibitor plus aspirin

    Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion 1. Prasugrel plus Aspirin arm 2. Clopidogrel plus Aspirin arm

    Also known as: Prasugrel plus Aspirin or Clopidogrel plus Aspirin

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac events (MACE)

    A composite of death, myocardial infarction, or stent thrombosis

    Time frame: 1-year after randomization

Secondary outcomes

  1. All-cause death

    Death by any cause

    Time frame: 1-year after randomization

  2. Cardiac death

    Death by cardiac cause

    Time frame: 1-year after randomization

  3. Myocardial infarction

    Myocardial infarction

    Time frame: 1-year after randomization

  4. Stent thrombosis

    Definite or probable stent thrombosis

    Time frame: 1-year after randomization

  5. Target lesion revascularization

    Repeat revascularization for target lesion of index PCI

    Time frame: 1-year after randomization

  6. Target vessel revascularization

    Repeat revascularization for target vessel of index PCI

    Time frame: 1-year after randomization

  7. Any revascularization

    Any repeat revascularization

    Time frame: 1-year after randomization

  8. A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization

    A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization

    Time frame: 1-year after randomization

  9. A composite of all-cause death/myocardial infarction

    A composite of all-cause death/myocardial infarction

    Time frame: 1-year after randomization

  10. A composite of cardiac death/myocardial infarction

    A composite of cardiac death/myocardial infarction

    Time frame: 1-year after randomization

  11. Cerebrovascular accident

    Cerebrovascular accident

    Time frame: 1-year after randomization

  12. A composite of all-cause death/myocardial infarction/cerebrovascular accident

    A composite of all-cause death/myocardial infarction/cerebrovascular accident

    Time frame: 1-year after randomization

  13. A composite of cardiac death/myocardial infarction/cerebrovascular accident

    A composite of cardiac death/myocardial infarction/cerebrovascular accident

    Time frame: 1-year after randomization

  14. A composite of cardiac death/myocardial infarction/stent thrombosis

    A composite of cardiac death/myocardial infarction/stent thrombosis

    Time frame: 1-year after randomization

  15. Bleeding by BARC types 3 or 5

    Bleeding defined by Bleeding Academic Research Consortium (BARC) types 3 or 5

    Time frame: 1-year after randomization

  16. Bleeding by BARC types 2, 3, or 5

    Bleeding defined by BARC types 2, 3 or 5

    Time frame: 1-year after randomization

  17. Net adverse clinical events

    MACE + bleeding by BARC types 3 or 5

    Time frame: 1-year after randomization

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jun 2027, 89 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 89 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 10, 2019
StartActual
Jan 13, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04014803
Collaborators
Inje University Ilsan Paik Hospital, Seoul St. Mary's Hospital, Mediplex Sejong Hospital, Chonnam National University Hospital, Sejong General Hospital, Wonkwang University Hospital, Gachon University Gil Medical Center, Keimyung University Dongsan Medical Center, Chungbuk National University Hospital, Yeungnam University Hospital, Chungnam National University Hospital, Wonju Severance Christian Hospital, Konkuk University Chungju Hospital, Chung-Ang University Hospital, Dankook University, Incheon St.Mary's Hospital, Gyeongsang National University Hospital, Soonchunhyang University Hospital, Ewha Womans University Seoul Hospital
Responsible party
Joo-Yong Hahn (Professor, Samsung Medical Center) — Principal investigator
First posted
Jul 10, 2019
Start date
Jan 13, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 9, 2026

Study contacts

Joo-Yong Hahn, MD, PhD
Contact
ichjy1@gmail.com
82-2-3410-1246
Ki hong Choi, MD, PhD
Contact
cardiokh@gmail.com
82-2-3410-3419
Joo-Yong Hahn, MD, PhD
study chair · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion